Image

Tolerance and Acceptability Evaluation of an Oral Nutrition Supplement

Tolerance and Acceptability Evaluation of an Oral Nutrition Supplement

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

To evaluate the tolerance (gastrointestinal) and acceptability of a new Oral Nutrition Supplement in patients with or at risk of disease related malnutrition, taken either orally or via a feeding tube

Description

To evaluate tolerance and acceptability of a new Oral Nutrition Supplement in patients with or at risk of malnutrition, who require supplementary nutrition support, either taken orally or with a feeding tube. Outcomes of GI effects, compliance, product preference, convenience etc. will be recorded.

To obtain data to support an ACBS submission (to allow for prescription in the community at NHS expense).

Eligibility

Inclusion Criteria:

  • Adult patients (≥18 years) who are able to communicate clearly.
  • Diagnosis of renal disease or confirmed requirement for protein supplementation by a suitably qualified health care professional (e.g. dietitian)
  • Participants with or at risk of malnutrition as determined by the SGA nutritional screening tool, MUST and/or by professional clinical judgement.
  • Participants expected to require an ONS for at least 28 days from baseline, to take flavour variants orally and neutral via feeding tube.
  • Informed consent obtained.

Exclusion Criteria:

  • Participation in any other studies involving investigational or marketed products concomitantly or within seven days prior to entry into the study
  • Patients with medical or dietary contraindication to any ingredients (see appendix 2 of protocol for full list.)
  • No feeding tube for any patient taking the neutral variant.
  • Patients with significant hepatic impairment.
  • Patients with dysphagia requiring IDDSI level 1 (or higher) fluids.
  • Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms.
  • Any patients having taken antibiotics over the previous 2 weeks leading up to the study.
  • Any participant unable to give consent i.e., those with dementia.
  • Participants under 18 years of age.
  • Individuals who do not have sufficient proficiency with English language
  • Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements.

Study details
    Disease Related Malnutrition

NCT07417514

Aymes International Limited

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.